STOCK TITAN
  1. Home
  2. News
  3. TEM

Tempus AI Stock Price, News & Analysis

TEM Nasdaq

Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.

Tempus AI Inc (NASDAQ: TEM) pioneers AI-driven healthcare solutions through its proprietary data integration platform. This news hub provides investors and healthcare professionals with essential updates on the company's technological advancements, strategic partnerships, and financial developments.

Access real-time announcements covering TEM's innovations in diagnostic analytics, generative AI applications, and healthcare data ecosystem expansions. Our curated collection includes earnings reports, regulatory filings, and analyses of platform enhancements that power precision medicine.

Key focus areas include AI-powered laboratory solutions, clinical research collaborations, and progress in breaking healthcare data silos. Stay informed about TEM's role in advancing personalized diagnostics through machine learning and large language model implementations.

Bookmark this page for verified updates on TEM's operational milestones, directly sourced from official communications. Monitor how the company continues redefining medical data utilization while maintaining HIPAA-compliant security standards across its platform.

News

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) has unveiled xM for treatment response monitoring (TRM), a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors. The assay, currently available for research use only with clinical availability expected later in 2025, monitors circulating tumor DNA (ctDNA) changes from blood samples to assess early molecular response in patients receiving immunotherapy. The technology utilizes a multi-parametric algorithm that integrates copy number variations and variant allele frequencies for comprehensive tumor fraction estimation. According to 2023 data, while 56.55% of advanced cancer patients were eligible for immune-checkpoint inhibitors, only 20.13% showed response. Tempus is presenting new data at the 2025 ASCO Annual Meeting, demonstrating how xM for TRM can detect molecular response within six weeks of treatment initiation, potentially enabling clinicians to optimize therapeutic strategies earlier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.02%
Tags
none
-
News

Introducing Tempus One in the EHR with Integrated Guidelines

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) has announced significant enhancements to Tempus One, its generative AI clinical assistant, by integrating it directly with electronic health record (EHR) systems. The expanded platform now incorporates ASCO clinical practice guidelines and features comprehensive workflow assistance tools. Key capabilities include pre-appointment preparation, real-time support during patient visits, and post-appointment documentation assistance. The system can analyze patient data, transcribe conversations, and facilitate clinical trial matching. Through its Agent Builder GenAI tool, Tempus has developed over 1,000 AI agents and is now extending this capability to select healthcare partners for custom solution development. The platform leverages Tempus's extensive EHR integrations across the U.S., accessing real-time clinical, molecular, and imaging data from millions of patients to streamline physician workflows and enhance treatment decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) has launched its Fuses program, leveraging its extensive multimodal dataset to develop AI-enabled diagnostic platforms for precision medicine. The company's data library includes over 40 million research records, featuring 1.5 million records with matched clinical-genomic data, 2 million imaging records, and 300,000 records with genomic and transcriptomic data. The program builds on Tempus' earlier success with its Immune Profile Score (IPS) for metastatic pan-solid tumors. Fuses aims to develop clinically validated algorithmic diagnostics to enable personalized patient care, identify treatment responses, and predict adverse events. The foundational model will help understand clinical trial failures, identify new drug indications, optimize trial design, and uncover combination therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) announced the acceptance of ten abstracts for presentation at the 2025 ASCO Annual Meeting in Chicago. The presentations showcase Tempus's AI-driven solutions in precision oncology, including tumor monitoring, genomic sequencing, and biomarker profiling. Key highlights include their TIME network's success in screening 1.28M patients for clinical trials resulting in 573 consents in 2024, the effectiveness of Tempus xM for monitoring disease recurrence in colorectal cancer patients, advancements in using large language models for clinical data abstraction, the capabilities of Tempus xH in detecting genetic mutations in AML patients, and the utility of Tempus xM in monitoring treatment response in patients receiving immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
none
-
News

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has announced its involvement in nearly 1,500 research projects over the past decade, demonstrating its commitment to advancing precision medicine through AI technology. The company's contributions include approximately 1,000 biopharma research projects and 500 provider-led research initiatives through its diagnostic portfolio and biological modeling capabilities.

Since its founding in 2015, Tempus has collaborated with academic institutions, health systems, and biopharma organizations, supporting over 200 projects with diagnostic assays and about 65 research initiatives through its biological modeling lab. The company's AI-powered platform provides comprehensive solutions for clinical and therapeutic research, focusing on therapy selection and drug discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.23%
Tags
none
-
News

New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

Rhea-AI Summary
Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has published a study in Genetics in Medicine highlighting the success of their Patient for Life™ program. The program systematically reanalyzes exome test results, leading to a 5% diagnostic success rate for previously negative or uninformative cases. The study, analyzing cases from 2012-2021, revealed that 23% of cases underwent at least one reanalysis. Notably, 54% of lab-driven reanalyses resulted in diagnostic reclassification, compared to just 4% for clinician-requested reanalyses. The program's efficiency is demonstrated by the fact that 80% of reclassified cases identified new diagnoses that might have been missed without the laboratory-initiated workflow. This initiative is particularly significant given that rare diseases affect 25-30 million Americans, with over 100 new gene-disease associations discovered annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
News

Tempus to Present at the William Blair 45th Annual Growth Stock Conference

Rhea-AI Summary

Tempus AI (NASDAQ: TEM), a technology company focused on AI-driven precision medicine and patient care, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The conference is scheduled for June 3-5, 2025 in Chicago, IL. The company's Chief Financial Officer, Jim Rogers, will deliver a presentation on June 5. The presentation will be accessible via a live audio webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.87%
Tags
conferences
-
News

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) has announced a collaboration with Verastem Oncology to develop a companion diagnostic (CDx) test for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC). The partnership follows Tempus' successful confirmatory testing in Verastem's Phase 2 RAMP-201 trial, which led to the FDA's accelerated approval of the combination treatment using avutometinib and defactinib. Tempus' FDA-approved xT CDx assay is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 trial to assess KRAS status in LGSOC patients. LGSOC is a rare ovarian cancer affecting younger women, representing 6-10% of serous ovarian cancers, with high recurrence rates and poor chemotherapy response. The xT CDx test can detect alterations in 648 genes and microsatellite instability status using DNA from tumor tissue and matched normal specimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
fda approval
-
News

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

Rhea-AI Summary

Tempus AI (NASDAQ: TEM) has announced a multi-year strategic collaboration with Boehringer Ingelheim to advance cancer research and drug development. The partnership will give Boehringer access to Tempus' de-identified database of molecular, clinical, and imaging data, along with its analytical platform, Lens.

The collaboration aims to leverage data and AI to guide biomarker development, patient stratification, drug combination hypotheses, and novel target discovery. This partnership builds on previous foundational work between the two companies, combining Boehringer's pre-clinical experimental data with Tempus' real-world data to enhance understanding of cancer biology and accelerate drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none
News

Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025

Rhea-AI Summary
Tempus AI (NASDAQ: TEM) announced the presentation of six research posters at ISPOR 2025 in Montreal, showcasing their work in AI and real-world data applications for healthcare. The presentations include one oral presentation on oncology trial emulation and five poster presentations focusing on: 1. Impact of adverse event definitions in immune-related events 2. Comparison of Tempus database with SEER cancer registry 3. Assessment of oncology treatment data completeness 4. NGS testing timing effects in colorectal cancer 5. Integration of sequencing, EHR, and claims data for lung cancer research The research demonstrates Tempus's efforts in combining clinical, molecular, and claims data to improve personalized cancer care and treatment strategies. Key findings include the impact of dataset features on trial emulations, varying immune-related adverse event detection rates, and the importance of timely NGS testing in survival outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none

FAQ

What is the current stock price of Tempus AI (TEM)?

The current stock price of Tempus AI (TEM) is $58.66 as of June 5, 2025.

What is the market cap of Tempus AI (TEM)?

The market cap of Tempus AI (TEM) is approximately 9.2B.
Stock TEM logo
Tempus AI

Nasdaq:TEM

TEM Rankings

#897 Ranked by Market Cap
N/A Ranked by Dividends

TEM Stock Data

9.21B
94.87M
47.69%
34.24%
8.23%
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
CHICAGO